.png)
Share
Bob Jahr
Outlook Therapeutics, Inc., a biopharmaceutical company dedicated to improving standards of care for retina diseases, has appointed Bob Jahr as Chief Executive Officer (CEO) and member of the Board of Directors.
Lawrence A. Kenyon, who has been serving as Chief Financial Officer (CFO) and interim CEO, will continue in his role as CFO and remain on the Board.
Mr. Jahr brings more than two decades of leadership experience across the biopharmaceutical industry, with a proven record in building and scaling commercial teams across therapeutic areas including rare disease, oncology, hematology, autoimmunology, neuroscience, cardiovascular, and inflammation. He has played key roles in advancing multiple billion-dollar assets and global franchises.
Most recently, Mr. Jahr served as Chief Commercial Officer for Sobi North America, overseeing commercial strategy, sales, marketing, operations, and market access while leading immunology and hematology franchises and global development asset teams. Prior to Sobi, he held senior leadership roles at UCB Pharma SA, where he managed international markets including China, Japan, and Brazil, and led U.S. payer value, pricing, and strategy functions. He began his career with Amgen, advancing through leadership roles in sales, marketing, operations, and market access.
“LYTENAVA™ (bevacizumab-vikg) has the potential to transform the global retina market,” said Mr. Jahr. “With commercial launch underway in Europe and anticipated FDA approval in the U.S., I am excited to join at such a pivotal moment and help establish Outlook Therapeutics as a leader in ophthalmology.”
Mr. Jahr holds an MBA and a B.S. in Business Administration and Management from the University of Montana.
